US20020001842A1 - Cytoplasmic transfer to de-differentiate recipient cells - Google Patents
Cytoplasmic transfer to de-differentiate recipient cells Download PDFInfo
- Publication number
- US20020001842A1 US20020001842A1 US09/736,268 US73626800A US2002001842A1 US 20020001842 A1 US20020001842 A1 US 20020001842A1 US 73626800 A US73626800 A US 73626800A US 2002001842 A1 US2002001842 A1 US 2002001842A1
- Authority
- US
- United States
- Prior art keywords
- cell
- cells
- cytoplasm
- oocyte
- donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Definitions
- the present invention relates to methods for “de-differentiating” and/or altering the life-span of desired recipient cells, preferably human somatic cells. These methods have application especially in the context of cell therapies and the production of genetically modified cells.
- a surrogate cytoplast such as from an ES cell of a less differentiated cell, preferably an oocyte or blastomere, or another embryonic cell type.
- compositions for therapeutic, dermatologic and/or cosmetic usage that contain cytoplasm derived from substantially undifferentiated or undifferentiated cells, preferably an oocyte or blastomere, or purified active components of same.
- the present invention provides novel methods for producing cells, preferably mammalian cells and, most preferably, human cells that have been de-differentiated and/or which have an altered (increased) life-span by the juxtaposition of the donor cell with cytoplasm from an undifferentiated or substantially undifferentiated cell, preferably an oocyte or blastomere, or another embryonic cell type.
- the present invention will be used to produce cells in a more primitive state, especially embryonic stem cells or inner cell mass cells.
- the resultant cells are useful in gene and cell therapies, and as donor cells or nuclei for use in nuclear transfer.
- Optye In the present invention, this refers to any oocyte, preferably a mammalian oocyte, that develops from an oogonium and, following meiosis, becomes a mature ovum.
- Methodaphase II ooctye The preferred stage of maturation of oocytes used for nuclear transfer (First and Prather, Differentiation, 48:1-8). At this stage, the oocyte is sufficiently “prepared” to treat an introduced donor cell or nucleus as it does a fertilizing sperm.
- Donor Cell In the present invention, this refers to a cell wherein some or all of its cytoplasm is transferred to another cell (“recipient cell”).
- the donor cell is typically a primitive or embryonic cell type, preferably an oocyte, blastomere, or inner cell mass cell.
- Recipient Cell This refers to a cell into which all or part of the cytoplasm of a donor cell, wherein such donor cell is of a more primitive cell type relative to the recipient cell, is transferred. This transfer can be accomplished by different methods, e.g., microinjection or by contacting donor cells with liposomal encapsulated cytoplasm or enucleating the donor cell and incubating with cytoplasmic extract.
- the donor cell is an oocyte, blastomere or inner cell mass cell
- the recipient cell is a somatic cell, preferably a human somatic cell.
- blastomere Embryonic, substantially undifferentiated cells contained in blastocyst stage embryos.
- Embryonic cell or embryonic cell type In the present invention, this will refer to any cell, e.g., oocyte, blastomere, embryonic stem cell, inner cell mass cell, or primordial germ cell, wherein the introduction of cytoplasm therefrom into a differentiated cell, e.g., human somatic cell in tissue culture, results in de-differentiation and/or lengthening of the life-span of such differentiated cell.
- a differentiated cell e.g., human somatic cell in tissue culture
- Cell having altered life-span In the present invention this refers to the change in cell life-span (lengthening) that results when cytoplasm of a more primitive or less differentiated cell type, e.g., an embryonic cell or embryonic cell type, e.g., oocyte or blastomere, is introduced into a desired differentiated cell, e.g., a cultured human somatic cell.
- a more primitive or less differentiated cell type e.g., an embryonic cell or embryonic cell type, e.g., oocyte or blastomere
- Embryonic stem cell In the present invention this refers to an undifferentiated cell that has the potential to develop into an entire organism, i.e., a cell that is able to propagate indefinitely, maintaining its undifferentiated state and, when induced to differentiate, be capable of giving rise to any cell type of the body.
- Nuclear Transfer Introduction of cell or nuclear DNA of donor cell into enucleated oocyte which cell or nucleus and oocyte are then fused to produce a nuclear transfer fusion or nucleus fusion embryo. This NT fusion may be used to produce a cloned embryo or offspring or to produce ES cells.
- Telomerase A ribonucleoprotein (RNP) particle and polymerase that uses a portion of its internal RNA moiety as a template for telomere repeat DNA synthesis (U.S. Pat. No. 5,583,016; Yu et al, Nature, 344:126 (1990); Singer and Gottschling, Science, 266:404 (1004); Autexier and Greider, Genes Develop., 8:563 (1994); Gilley et al, Genes Develop., 9:2214 (1995); McEachern and Blackburn, Nature, 367:403 (1995); Blackburn, Ann. Rev. Biochem., 61:113 (1992); Greider, Ann Rev.
- RNP ribonucleoprotein
- RNA i.e., as opposed to DNA
- Telomerases extend the G strand of telomeric DNA.
- telomeres may be extremely processive, with the Tetrahymena telomerase adding an average of approximately 500 bases to the G strand primer before dissociation of the enzyme (Greider, Mol. Cell. Biol., 114572 (1991).)
- Genetically modified or altered refers to cells that contain one or more modifications in their genomic DNA, e.g., additions, substitutions and/or deletions.
- De-differentiation In the present invention, this refers to the changes in a differentiated cell, e.g., human somatic cell in tissue culture, that result upon introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., an oocyte or other embryonic cell.
- a differentiated cell e.g., human somatic cell in tissue culture
- cytoplasm from a more primitive, less differentiated cell type, e.g., an oocyte or other embryonic cell.
- Totipotent In the present invention this refers to a cell that gives rise to all of the cells in a developing body, such as an embryo, fetus, an animal.
- the term “totipotent” can also refer to a cell that gives rise to all of the cells in an animal.
- a totipotent cell can give rise to all of the cells of a developing cell mass when it is utilized in a procedure for creating an embryo from one or more nuclear transfer steps.
- An animal may be an animal that functions ex utero.
- An animal can exist, for example, as a live born animal.
- Totipotent cells may also be used to generate incomplete animals such as those useful for organ harvesting, e.g., having genetic modifications to eliminate growth of a head such as by manipulation of a homeotic gene.
- Ungulate In the present invention this refers to a four-legged animal having hooves.
- the ungulate is selected from the group consisting of domestic or wild representatives of bovids, ovids, cervids, suids, equids, and camelids. Examples of such representatives are cows or bulls, bison, buffalo, sheep, big-horn sheep, horses, ponies, donkeys, mule, deer, elk, caribou, goat, water buffalo, camels, llama, alpaca, and pigs. Especially preferred in the bovine species are Bos Taurus, Bos Indicus , and Bos buffaloes cows or bulls.
- “Immortalized” or “permanent” cell can refer to cells that have exceeded the Hayflick limit.
- the Hayflick limit can be defined as the number of cell divisions that occur before a cell line becomes senescent. Hayflick set this limit to approximately 60 divisions for most non-immortalized cells. See, e.g., Hayflick and Moorhead, 1971, Exp. Cell. Res., 25:585-621; and Hayflick, 1965, Exp. Cell Research, 37:614-636, incorporated herein by reference in their entireties, including all figures, tables and drawings.
- an immortalized cell line can be distinguished from non-immortalized cell lines if the cells in the cell line are able to undergo more than 60 divisions. If the cells of a cell line are able to undergo more than 60 cell divisions, the cell line is an immortalized or permanent cell line.
- the immortalized cells of the invention are preferably able to undergo more than 70 divisions, are more preferably able to undergo more than 90 divisions, and are most preferably able to undergo more than 90 cell divisions.
- immortalized or permanent cells can be distinguished from non-immortalized and non-permanent cells on the basis that immortalized and permanent cells can be passaged at densities lower than those of non-immortalized cells.
- immortalized cells can be grown to confluence (e.g., when a cell monolayer spreads across an entire plate) when plating conditions do not allow physical contact between the cells.
- immortalized cells can be distinguished from non-immortalized cells when cells are plated at cell densities where the cells do not physically contact one another.
- Cells In the present invention this term refers to one or more cells that are static or undergoing cell division in a liquid medium. Nearly any type of cell can be placed in cell culture conditions. Cells may be cultured in suspension and/or in monolayers with one or more substantially similar cells. Cells may be cultured in suspension and/or in monolayers with heterogeneous population cells. The term heterogeneous as utilized in the previous sentence can relate to any cell characteristics, such as cell type and cell cycle stage, for example. Cells may be cultured in suspension and/or in monolayers with feeder cells.
- Feeder Cells This refers to cells grown in co-culture with other cells.
- Feeder cells include, e.g., fibroblasts, fetal cells, oviductal cells, and may provide a source of peptides, polypeptides, electrical signals, organic molecules (e.g., steroids), nucleic acid molecules, growth factors, cytokines, and metabolic nutrients to cells co-cultured therewith.
- Some cells require feeder cells to be grown in tissue culture.
- Reprogram This term as used in the present invention refers to materials and methods that can convert a differentiated cell into a less differentiated, more primitive cell type, e.g., an embryonic stem cell.
- Embryo In the present invention this refers to a developing cell mass that has not implanted into the uterine membrane of a maternal host.
- the term “embryo” as used herein can refer to a fertilized oocyte, a cybrid (defined herein), a pre-blastocyst stage developing cell mass, and/or any other developing cell mass that is at a stage of development prior to implantation into the uterine membrane of a maternal host.
- Embryos of the invention may not display a genital ridge.
- an “embryonic cell” is isolated from and/or has arisen from an embryo.
- “Fetus” In the present invention refers to a developing cell mass that has implanted into the uterine membrane of a maternal host.
- a fetus can include such defining features as a genital ridge, for example.
- a genital ridge is a feature easily identified by a person of ordinary skill in the art and is a recognizable feature in fetuses of most animal species.
- Fetal cell as used herein can refer to any cell isolated from and/or has arisen from a fetus or derived from a fetus.
- Non-fetal cell refers to a cell that is not derived or isolated from a fetus.
- “Senescence” In the present invention this refers to the characteristic slowing of growth of non-immortal somatic cells in tissue culture after cells have been maintained in culture for a prolonged period. Non-immortal cells characteristically have a defined life-span before they become senescent and die.
- the present invention alleviates or prevents senescence by the introduction of cytoplasm from a donor cell, typically an oocyte or blastomere, into a recipient cell, e.g., a cultured human somatic cell.
- the present invention provides novel methods for de-differentiating and/or altering the life-span of desired cells, preferably mammalian cells and, most preferably, human or other primate cells by the introduction of cytoplasm from a more primitive cell type, typically an undifferentiated or substantially undifferentiated cell, e.g., an oocyte or blastomere.
- desired cells preferably mammalian cells and, most preferably, human or other primate cells by the introduction of cytoplasm from a more primitive cell type, typically an undifferentiated or substantially undifferentiated cell, e.g., an oocyte or blastomere.
- differentiated adult cells may be effectively “reprogrammed” by nuclear transfer
- differentiated cells could be effectively “reprogrammed” or “de-differentiated” and/or have their life-span altered (increased) by the introduction of cytoplasm from that of undifferentiated or substantially undifferentiated cell, e.g., an oocyte or blastomere or another embryonic cell type.
- the cytoplasm of cells in early or primitive states of development contains one or more substances, e.g., transcription factors and/or other substances that act to trigger or promote cell differentiation.
- substances e.g., transcription factors and/or other substances that act to trigger or promote cell differentiation.
- one substance likely contained therein that affects the state of cell differentiation is telomerase.
- Another substance is OCT-4 and REX.
- Applicant does not wish to be bound to this theory as it is not necessary for an understanding of the invention.
- a recipient cell will typically be dedifferentiated in vitro by the introduction of an effective amount of cytoplasm from a donor cell, i.e., an undifferentiated or substantially undifferentiated cell, e.g., an oocyte or blastomere.
- This introduction or transfer of cytoplasm can be effected by different methods, e.g., by microinjection or by use of a liposomal delivery system.
- a preferred means comprises the introduction of cytoplasm blebs derived from ES cells, oocytes or other embryonic cells into desired differentiated cells, e.g. mammalian or other cells which are at or near senescence.
- cytoplasm blebs can be introduced into genetically modified mammalian cells in order to rejuvenate such cells, e.g. prior to their usage for cell therapy.
- cytoplasmic blebs can be contacted with nuclei from differentiated cells to induce rejuvenation.
- the recipient cell can be of any species and may be heterologous to the donor cell, e.g., amphibian, mammalian, avian, with mammalian cells being preferred.
- Especially preferred recipient cells include human and other primate cells, e.g., chimpanzee, cynomolgus monkey, baboon, other Old World monkey cells, caprine, equine, porcine, ovine, and other ungulates, murine, canine, feline, and other mammalian species.
- the recipient cell can be any differentiated cell type. Suitable examples thereof include epithelial cells, endothelial cells, fibroblasts, keratinocytes, melanocytes and other skin cell types, muscle cells, bone cells, immune cells such as T and B-lymphocytes, oligodendrocytes, dendritic cells, erythrocytes and other blood cells; pancreatic cells, neural and nerve cell types, stomach, intestinal, esophageal, lung, liver, spleen, kidney, bladder, cardiac, thymus, corneal, and other ocular cell types, etc.
- the methods have application in any application wherein a source of cells that are in a less differentiated state would be desirable.
- the transferred cytoplasm will be obtained from a “donor” cell that is in a less differentiated state or more primitive state than the recipient cell.
- the cytoplasm will be derived from oocytes or cells of early stage embryos, e.g., blastomeres or inner cell mass cells derived from early stage embryos.
- the donor cytoplasm be obtained from oocytes or other embryonic cells that are in an undifferentiated or substantially undifferentiated state.
- Bovine oocytes are a preferred source because they can be readily obtained in large quantities from slaughterhouses.
- donor cytoplasm be obtained from an oocyte or other cell that expresses or does not express cell markers which are characteristic of an undifferentiated, embryonic cell type.
- markers on primate ES cells include, by way of example, SSEA-1 ( ⁇ ); SSEA-3 (+); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+).
- telomerase and/or a DNA sequence or other compound that provides for the expression of telomerase be introduced into the recipient cell, e.g., a mammalian cell and, more preferably, a human or non-human primate cell.
- a mammalian cell e.g., a mammalian cell and, more preferably, a human or non-human primate cell.
- the isolation of telomerase and cloning of the corresponding DNA has been reported prior to the present invention.
- WO 98/14593 published Apr. 9, 1998, by Cech et al, reports telomerase nucleic acid sequences derived from Eeuplotes aediculatus, Saccharomyces, Schizosaccharomyces , and human, as well as polypeptides comprising telomerase protein subunits.
- telomere reverse transcriptase the catalytic protein subunit of human telomerase.
- U.S. Pat. Nos. 5,837,857 and 5,583,414 describe nucleic acids encoding mammalian telomerases.
- desired cells e.g., cultured human somatic cells
- cytoplasm of a more primitive cell type e.g., an oocyte or embryonic cell type alone or in conjunction with telomerase.
- the introduction of cytoplasm from a donor oocyte or embryonic cell, e.g., blastomere may be accomplished by various methods. For example, this can be effected by microsurgically removing part or all of the cytoplasm of a donor oocyte or blastomere or other embryonic cell type with a micropipette and microinjecting such cytoplasm into that of a recipient mammalian cell.
- cytoplasm and/or telomerase or telomerase DNA can be introduced using a liposomal delivery system.
- the present methods should provide a means of producing embryonic stem cells, e.g., mammalian embryonic stem cells, and most desirably, human embryonic stem cells, by reprogramming or de-differentiating desired cells in tissue culture. These cells are desirable from a therapeutic standpoint since such cells can be used to give rise to any differentiated cell type.
- the resultant differentiated cell types may be used in cell transplantation therapies.
- Another significant application of the present invention is for gene therapy.
- desired cells e.g., mammalian cells and, more preferably, human somatic cell types.
- methods for effecting site-specific insertion of desired DNAs via homologous recombination are well known in the art.
- the present invention will alleviate this inherent constraint of gene and cell therapy by introducing the cytoplasm of an oocyte or other embryonic cell type into recipient cells prior, concurrent or subsequent to genetic modification.
- the introduction of such cytoplasm alone or in combination with telomerase or a DNA or another compound that results in the expression of telomerase will reprogram the genetically modified cell and enable it to have a longer life-span in tissue culture.
- Such reprogramming can be effected once or repeatedly during genetic modification of recipient cells. For example, in the case of very complex genetic modifications, it may be necessary to “reprogram” recipient cells several times by the repeated introduction of donor cytoplasm to prevent senescence. The optimal frequency of such reprogramming will be determined by monitoring the doubling time of the cells in tissue culture such that the cells are reprogrammed before they become senescent.
- the resultant reprogrammed genetically modified cells which have a longer life-span as a result of reprogramming, may be used for cell and gene therapy. Moreover, these cells may be used as donor cells for nuclear transfer procedures or for the production of chimeric animals.
- the present methods will make it possible to produce cloned and chimeric animals having complex genetic modifications. This will be especially advantageous for the production of animal models for human diseases. Also, the present methods will be beneficial in situations wherein the expression of a desired gene product or phenotype is dependent upon the expression of different DNA sequences, or for gene research involving the interrelated effects of different genes on one another. Moreover, it is anticipated that the present methods will become very important as the interrelated effects of the expression of different genes on others becomes more understood.
- Yet another application of the present invention is for alleviating the effects of aging.
- mammalian cells have a finite life-span in tissue culture, they similarly have a finite life-span in vivo. This finite life-span is hypothesized to explain why organisms, including humans, have a normal maximum life-span, determined by the finite life-span of human somatic cells.
- the present invention will alleviate the effects of aging by taking mammalian cells from an individual and altering (lengthening) the life-span of such cells by introduction of cytoplasm from an oocyte or other embryonic cell type, e.g., blastomere.
- the resultant rejuvenated cells may be used to produce differentiated cell types in tissue culture and these cells can then be introduced into the individual. This can be used, e.g., to rejuvenate the immune system of an individual. Such rejuvenation should be useful in the treatment of diseases thought to be of immune origin, e.g., some cancers.
- the subject methods may be used for the production of autologous grafts, e.g., skin grafts, which can be used in the case of tissue injury or elective surgery.
- autologous grafts e.g., skin grafts
- cytoplasm-containing compositions for treating the effects of chronologic and UV-induced aging on the skin.
- various physical changes may be manifested including discoloration, loss of elasticity, loss of radiance, and the appearance of fine lines and wrinkles.
- cytoplasm-containing compositions e.g., bovine oocytes, optionally further including telomerase or a telomerase DNA construct, can be packaged in liposomes to facilitate internalization into skin cells upon topical application.
- compositions that facilitate absorption into the skin, e.g., DMSO.
- DMSO e.g., DMSO
- These compositions may be topically applied to areas of the skin wherein the effects of aging are most pronounced, e.g., the skin around the eyes, the neck and the hands.
- Still another application of the present invention is for identification of the substance or substances found in cytoplasm that induces de-differentiation. This can be effected by fractionation of cytoplasm and screening these fractions to identify those which contain substances that result in effective rejuvenation or reprogramming when transferred into recipient cells, e.g., human differentiated cell types.
- the component(s) contained in oocyte cytoplasm responsible for reprogramming or rejuvenation can be identified by subtractive hybridization by comparing mRNA expression in early stage embryos and oocytes to that of more differentiated embryos.
- such component(s) may comprise nucleic acids, in particular maternal RNAs, or proteins encoded thereby.
- nucleic acids in particular maternal RNAs, or proteins encoded thereby.
- maternal RNA's that are stored in the egg very early on but which are not detected past the blastula stage.
- Maternal RNA levels have been quantified for different species, i.e., rabbit, cow, pig, sheep and mouse.
- RNA in Drosophila oocyte encodes a protein that may bind to a tyrosine kinase receptor present in adjacent follicle cells that may initiate various events leading to dorsal follicle cell differentiation which act to delimit and orient the future dorsoventral axis of the embryo.
- a maternal mRNA in silkworm oocytes encodes a protein that may be a structural component necessary for formation of the cellular blastoderm of the embryo, and that the association of such maternal mRNA with cortical cytoskeleton may participate in the synthesis of new cytoskeleton or related structures during blastoderm development. (Kastern et al, Devel., 108(3):497-505(1990).)
- cytoplasm apparently contains some component that results in cell reprogramming
- compounds, likely nucleic acids and/or proteinaceous compounds which are present in the cytoplasm of oocytes and early embryos that, under appropriate conditions, provide for reprogramming or de-differentiation of desired cells. This will be effected by fractionation of cytoplasm into different fractions, e.g., based on size or isoelectric point, and ascertaining those factors which effect de-differentiation or reprogramming when transferred to differentiated cell types.
- the factors responsible for reprogramming may be identified by subtractive or differential hybridization, essentially by identifying those mRNAs which are present in oocytes that are lost after the embryo has differentiated beyond a certain stage, e.g., past the blastula stage of development, and identifying those of which are involved in de-differentiation or reprogramming.
- the invention includes the identification of the specific cytoplasmic materials, e.g., polypeptides and/or nucleic acid sequences, which when transferred into a differentiated cell provide for de-differentiation or reprogramming. Based on what has been reported with respect to maternal RNAs, it is anticipated that the active materials responsible for de-differentiation or reprogramming may include maternal RNAs or polypeptides encoded thereby.
- specific cytoplasmic materials e.g., polypeptides and/or nucleic acid sequences
- nucleic acid(s) or polypeptides After such nucleic acid(s) or polypeptides have been identified and sequenced, they will be produced by recombinant methods. It is anticipated that these recombinantly produced nucleic acids or polypeptides will be sufficient to induce reprogramming or de-differentiation of desired cells.
- the invention further encompasses assays wherein oocyte cytomplasm or cytoplasm from ES cells is fractionated into different fractions, e.g. based on molecular weight, isoelectric point, gel filtration, and salt precipitation, which are added into different microwells that contain one or more isolated nuclei from desired differentiated cells, e.g., mammalian, amphibian, avian, or insect cells and a screening assay conducted to identify mRNAs such as REX or OCT-4 that are released from the nuclei. For example, such mRNAs may be identified by PCR amplification and detection.
- PCR screening assays may be conducted wherein ooplasm can be added to desired differentiated cells and assays conducted to identify what mRNAs, e.g. REX or OCT-4, are released from the cell nuclei after introduction of the oocyte cytoplasm.
- mRNAs e.g. REX or OCT-4
- mRNAs can be identified by known methods, e.g. subtractive hybridization, differential display, and differential hyridization techniques. Essentially, these methods provide for the comparison of different populations of mRNAs in different cells, or cells at different times, and are conventionally used to identify genes that are expressed only under specific conditions or by specific types of cells.
- subtractive hybridization can be effected by use of oocyte RNAs which are subtracted with RNAs obtained from normal somatic cell RNAs. Thereby, RNAs that are involved in cell reprogramming can be identified.
- the invention further includes the reconstitution of nuclei isolated from desired differentiated cells, e.g. those which are derived from differentiated cells in tissue culture, which potentially may be genetically modified by contacting such isolated nuclei with cytoplasm fractionated from oocytes, blastomeres or ES cells, and the addition of such reconstituted nuclei to cytoplasts, thereby producing a rejuvenated cell having increased proliferation potential and lifespan.
- desired differentiated cells e.g. those which are derived from differentiated cells in tissue culture, which potentially may be genetically modified by contacting such isolated nuclei with cytoplasm fractionated from oocytes, blastomeres or ES cells, and the addition of such reconstituted nuclei to cytoplasts, thereby producing a rejuvenated cell having increased proliferation potential and lifespan.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/736,268 US20020001842A1 (en) | 1999-06-30 | 2000-12-15 | Cytoplasmic transfer to de-differentiate recipient cells |
US10/831,599 US20040199935A1 (en) | 1999-06-30 | 2004-04-23 | Cytoplasmic transfer to de-differentiate recipient cells |
US12/700,545 US20110171185A1 (en) | 1999-06-30 | 2010-02-04 | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof |
US12/787,175 US20110286978A1 (en) | 1999-06-30 | 2010-05-25 | Genetically Intact Induced Pluripotent Cells Or Transdifferentiated Cells And Methods For The Production Thereof |
US13/617,988 US20130104253A1 (en) | 1999-06-30 | 2012-09-14 | Cytoplasmic transfer to de-differentiate recipient cells |
US14/302,384 US9580683B2 (en) | 1999-06-30 | 2014-06-11 | ES cell cytoplasm or ooplasm transfer to rejuventate recipient cells |
US15/436,545 US20170226475A1 (en) | 1999-06-30 | 2017-02-17 | Cytoplasmic transfer to de-differentiate recipient cells |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14125099P | 1999-06-30 | 1999-06-30 | |
PCT/US2000/018063 WO2001000650A1 (en) | 1999-06-30 | 2000-06-30 | Cytoplasmic transfer to de-differentiate recipient cells |
US09/736,268 US20020001842A1 (en) | 1999-06-30 | 2000-12-15 | Cytoplasmic transfer to de-differentiate recipient cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/018063 Continuation-In-Part WO2001000650A1 (en) | 1999-06-30 | 2000-06-30 | Cytoplasmic transfer to de-differentiate recipient cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/831,599 Continuation US20040199935A1 (en) | 1999-06-30 | 2004-04-23 | Cytoplasmic transfer to de-differentiate recipient cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020001842A1 true US20020001842A1 (en) | 2002-01-03 |
Family
ID=22494867
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/736,268 Abandoned US20020001842A1 (en) | 1999-06-30 | 2000-12-15 | Cytoplasmic transfer to de-differentiate recipient cells |
US13/617,988 Abandoned US20130104253A1 (en) | 1999-06-30 | 2012-09-14 | Cytoplasmic transfer to de-differentiate recipient cells |
US14/302,384 Expired - Fee Related US9580683B2 (en) | 1999-06-30 | 2014-06-11 | ES cell cytoplasm or ooplasm transfer to rejuventate recipient cells |
US15/436,545 Abandoned US20170226475A1 (en) | 1999-06-30 | 2017-02-17 | Cytoplasmic transfer to de-differentiate recipient cells |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/617,988 Abandoned US20130104253A1 (en) | 1999-06-30 | 2012-09-14 | Cytoplasmic transfer to de-differentiate recipient cells |
US14/302,384 Expired - Fee Related US9580683B2 (en) | 1999-06-30 | 2014-06-11 | ES cell cytoplasm or ooplasm transfer to rejuventate recipient cells |
US15/436,545 Abandoned US20170226475A1 (en) | 1999-06-30 | 2017-02-17 | Cytoplasmic transfer to de-differentiate recipient cells |
Country Status (11)
Country | Link |
---|---|
US (4) | US20020001842A1 (es) |
EP (1) | EP1196426A4 (es) |
JP (1) | JP2003503071A (es) |
CN (1) | CN1362965A (es) |
AU (1) | AU782286B2 (es) |
BR (1) | BR0012099A (es) |
CA (1) | CA2377515C (es) |
IL (2) | IL147179A0 (es) |
MX (1) | MXPA01013450A (es) |
NZ (1) | NZ516236A (es) |
WO (1) | WO2001000650A1 (es) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002051997A1 (en) * | 2000-12-22 | 2002-07-04 | Aurox Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells |
US20040068760A1 (en) * | 1999-11-19 | 2004-04-08 | Robl James M. | Transgenic ungulates capable of human antibody production |
US20040072288A1 (en) * | 2000-12-22 | 2004-04-15 | Philippe Collas | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
WO2004094611A2 (en) * | 2003-04-21 | 2004-11-04 | University Of Massachusetts | Reprogramming nuclear function with somatic cell cytoplasm |
WO2004111195A2 (en) * | 2003-06-10 | 2004-12-23 | Trustees Of The University Of Pennsylvania | Methods and use of zona-free therapeutic cloning |
US20050097627A1 (en) * | 2002-11-08 | 2005-05-05 | Robl James M. | Transgenic ungulates having reduced prion protein activity and uses thereof |
US20050183145A1 (en) * | 1999-11-19 | 2005-08-18 | Goldsby Richard A. | Production of ungulates, preferably bovines that produce human immunoglobulins |
US20060041945A1 (en) * | 2004-04-22 | 2006-02-23 | Hematech, Llc | Transgenic animals and uses thereof |
US20060110830A1 (en) * | 2001-08-27 | 2006-05-25 | Advanced Cell Technology, Inc. | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US20060117394A1 (en) * | 1999-11-19 | 2006-06-01 | Hematech, Llc | Expression of xenogenous (human) imunoglobulins in cloned, transgenic ungulates |
US20070128662A1 (en) * | 2005-11-18 | 2007-06-07 | Isacoff Ehud Y | Photoreactive regulator of protein function and methods of use thereof |
WO2007047766A3 (en) * | 2005-10-14 | 2008-12-24 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
US20090276866A1 (en) * | 1999-11-19 | 2009-11-05 | Goldsby Richard A | Production of ungulates, preferably bovines that produce human immunoglobulins |
US7736895B2 (en) | 2000-12-22 | 2010-06-15 | Kyowa Hakko Kirin Co., Ltd. | Methods for altering cell fate |
US20100240132A1 (en) * | 2007-02-23 | 2010-09-23 | Robert Lanza | Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells |
US8664194B2 (en) | 2011-12-16 | 2014-03-04 | Moderna Therapeutics, Inc. | Method for producing a protein of interest in a primate |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2014197421A1 (en) | 2013-06-05 | 2014-12-11 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9580683B2 (en) | 1999-06-30 | 2017-02-28 | Advanced Cell Technology, Inc. | ES cell cytoplasm or ooplasm transfer to rejuventate recipient cells |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US9732128B2 (en) | 2010-10-22 | 2017-08-15 | Biotime, Inc. | Methods of modifying transcriptional regulatory networks in stem cells |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10501723B2 (en) | 2005-08-03 | 2019-12-10 | Astellas Institute For Regenerative Medicine | Methods of reprogramming animal somatic cells |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US11274281B2 (en) | 2014-07-03 | 2022-03-15 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
US11422125B2 (en) | 2015-03-23 | 2022-08-23 | Astellas Institute For Regenerative Medicine | Assays for potency of human retinal pigment epithelium (RPE) cells and photoreceptor progenitors |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU729377B2 (en) | 1997-10-23 | 2001-02-01 | Asterias Biotherapeutics, Inc. | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
BR0013844A (pt) * | 1999-09-07 | 2002-05-14 | Advanced Cell Tech Inc | Restauração de telÈmero e extensão de perìodo de vida da célula em animais clonados de células somáticas senescentes |
US20050042749A1 (en) | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
IL152741A0 (en) | 2000-05-17 | 2003-06-24 | Geron Corp | Neural progenitor cell populations |
EP1370132A2 (en) * | 2001-03-21 | 2003-12-17 | Geron Corporation | Use of telomerase reverse transcriptase to create homozygous knockout animals |
EP1385935A4 (en) | 2001-03-29 | 2004-09-15 | Ixion Biotechnology Inc | METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS IN THE PANCREAS DIFFERENTIATION PATHWAY |
GB0118984D0 (en) * | 2001-08-03 | 2001-09-26 | Intercytex Ltd | Fusion of cells |
WO2003018760A2 (en) * | 2001-08-24 | 2003-03-06 | Advanced Cell Technology, Inc. | Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy |
AU2002365162A1 (en) | 2001-11-14 | 2003-07-09 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
AU2003215280A1 (en) | 2002-02-15 | 2003-09-09 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
US7462448B2 (en) | 2002-08-02 | 2008-12-09 | Stratatech Corporation | Species specific DNA detection |
EP1391503A1 (en) * | 2002-08-12 | 2004-02-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | A method of cell re-programming by cytoplasmic transfer |
US7534761B1 (en) | 2002-08-21 | 2009-05-19 | North Western University | Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom |
US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
WO2004046167A2 (en) | 2002-11-14 | 2004-06-03 | Northwestern University | Synthesis and self-assembly of abc triblock bola peptide |
NZ541718A (en) | 2003-02-11 | 2008-04-30 | Univ Northwestern | Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon |
GB0316089D0 (en) * | 2003-07-09 | 2003-08-13 | Xo Bioscience Ltd | Differentiation method |
US7823789B2 (en) | 2004-12-21 | 2010-11-02 | Cognex Technology And Investment Corporation | Low profile illumination for direct part mark readers |
FR2861997A1 (fr) * | 2003-11-06 | 2005-05-13 | Fred Zacouto | Stimulateur cardiaque orthorythmique inotrope |
MXPA06006388A (es) | 2003-12-05 | 2006-09-04 | Univ Northwestern | Peptidos anfifilicos de auto-ensamble y metodos relacionados para el suministro del factor de crecimiento. |
WO2005056576A2 (en) | 2003-12-05 | 2005-06-23 | Northwestern University | Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
US20050214257A1 (en) | 2003-12-23 | 2005-09-29 | Northwestern University | Compositions and methods for controlling stem cell and tumor cell differentiation, growth, and formation |
KR20070108555A (ko) | 2005-03-04 | 2007-11-12 | 노오쓰웨스턴 유니버시티 | 혈관신생 헤파린 결합 펩티드 양친매성 화합물 |
FR2885368A1 (fr) * | 2005-05-04 | 2006-11-10 | Fred Zacouto | Systemes et procedes de regeneration cellulaire et utilisations de telles cellules regenerees |
WO2007026255A2 (en) * | 2005-06-22 | 2007-03-08 | Universitetet I Oslo | Dedifferentiated cells and methods of making and using dedifferentiated cells |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
JP2009024027A (ja) * | 2008-09-16 | 2009-02-05 | Tadashi Goino | 生理活性組成物 |
WO2010084275A1 (fr) * | 2009-01-26 | 2010-07-29 | Fred Zacouto | Procédé simplifié de reprogrammation génétique et épigénétique partielle de cellules. |
CN101798569B (zh) * | 2009-02-09 | 2012-11-21 | 北京瑞途之星科技有限公司 | 以卵裂后的发育胚胎替代卵母细胞的治疗性克隆新方法 |
EP2419116A1 (en) | 2009-04-13 | 2012-02-22 | North Western University | Novel peptide-based scaffolds for cartilage regeneration and methods for their use |
CN102266350A (zh) * | 2011-07-20 | 2011-12-07 | 黄必录 | 逆转干细胞衰老的方案 |
CN102321571A (zh) * | 2011-09-21 | 2012-01-18 | 王跃嗣 | 从分化细胞制备自体造血干细胞的方法 |
WO2016044721A1 (en) | 2014-09-19 | 2016-03-24 | Regenerative Medical Solutions, Inc. | Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells |
US9828634B2 (en) | 2015-01-22 | 2017-11-28 | Regenerative Medical Solutions, Inc. | Markers for differentiation of stem cells into differentiated cell populations |
CN106755113B (zh) * | 2016-12-29 | 2020-06-19 | 赛业(苏州)生物科技有限公司 | Es细胞基因打靶技术制备基因修饰小鼠的改进方法 |
WO2023038999A1 (en) * | 2021-09-07 | 2023-03-16 | Yuva Biosciences, Inc. | Compositions and methods for treating ovarian aging, ovarian diseases and conditions, and symptoms thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6344526A (ja) * | 1986-08-12 | 1988-02-25 | Kingo Yoshida | 幼若細胞の細胞質・ミトコンドリア・イントロン他注入による若返り長寿法 |
US5480772A (en) | 1993-02-03 | 1996-01-02 | Brandeis University | In vitro activation of a nucleus |
US5830651A (en) | 1995-06-01 | 1998-11-03 | Signal Pharmaceuticals, Inc. | Human oligodendroglial progenitor cell line |
GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
WO1997035967A2 (en) | 1996-03-28 | 1997-10-02 | Cold Spring Harbor Laboratory | Transgenic organisms with altered telomerase activity |
NZ334016A (en) * | 1996-08-19 | 2000-08-25 | Univ Massachusetts | Embryonic stem cell lines produced by cross species nuclear transplantation |
US20010012513A1 (en) | 1996-08-19 | 2001-08-09 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US6011197A (en) * | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
AU8587598A (en) * | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
GB9809178D0 (en) * | 1998-04-29 | 1998-07-01 | Univ Edinburgh | Nuclear reprogramming of somatic cells |
EP1204790A4 (en) * | 1999-04-23 | 2004-08-04 | Monica Palacios-Boyce | MICROELECTROMECHANICAL DEVICE FOR HANDLING CELLS OR EMBRYONS, KITS THEREFOR, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE USE THEREOF |
MXPA01013450A (es) | 1999-06-30 | 2003-09-04 | Advanced Cell Tech Inc | Transferencia citoplasmica para celulas receptoras de-diferenciacion. |
US20040199935A1 (en) | 1999-06-30 | 2004-10-07 | Chapman Karen B. | Cytoplasmic transfer to de-differentiate recipient cells |
CA2394614A1 (en) * | 1999-12-20 | 2001-06-28 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Embryonic or stem-like cells produced by cross species nuclear transplantation |
WO2003018780A1 (en) | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
-
2000
- 2000-06-30 MX MXPA01013450A patent/MXPA01013450A/es not_active Application Discontinuation
- 2000-06-30 WO PCT/US2000/018063 patent/WO2001000650A1/en active IP Right Grant
- 2000-06-30 BR BR0012099-5A patent/BR0012099A/pt not_active IP Right Cessation
- 2000-06-30 IL IL14717900A patent/IL147179A0/xx unknown
- 2000-06-30 EP EP00945032A patent/EP1196426A4/en not_active Withdrawn
- 2000-06-30 CA CA2377515A patent/CA2377515C/en not_active Expired - Lifetime
- 2000-06-30 AU AU59028/00A patent/AU782286B2/en not_active Ceased
- 2000-06-30 NZ NZ516236A patent/NZ516236A/xx not_active IP Right Cessation
- 2000-06-30 JP JP2001507057A patent/JP2003503071A/ja active Pending
- 2000-06-30 CN CN00809800A patent/CN1362965A/zh active Pending
- 2000-12-15 US US09/736,268 patent/US20020001842A1/en not_active Abandoned
-
2001
- 2001-12-19 IL IL147179A patent/IL147179A/en not_active IP Right Cessation
-
2012
- 2012-09-14 US US13/617,988 patent/US20130104253A1/en not_active Abandoned
-
2014
- 2014-06-11 US US14/302,384 patent/US9580683B2/en not_active Expired - Fee Related
-
2017
- 2017-02-17 US US15/436,545 patent/US20170226475A1/en not_active Abandoned
Cited By (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9580683B2 (en) | 1999-06-30 | 2017-02-28 | Advanced Cell Technology, Inc. | ES cell cytoplasm or ooplasm transfer to rejuventate recipient cells |
US20060117394A1 (en) * | 1999-11-19 | 2006-06-01 | Hematech, Llc | Expression of xenogenous (human) imunoglobulins in cloned, transgenic ungulates |
US20040068760A1 (en) * | 1999-11-19 | 2004-04-08 | Robl James M. | Transgenic ungulates capable of human antibody production |
US7803981B2 (en) | 1999-11-19 | 2010-09-28 | Kyowa Hakko Kirin Co., Ltd. | Transgenic ungulates capable of human antibody production |
US7820878B2 (en) | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
US20090276866A1 (en) * | 1999-11-19 | 2009-11-05 | Goldsby Richard A | Production of ungulates, preferably bovines that produce human immunoglobulins |
US20080040821A1 (en) * | 1999-11-19 | 2008-02-14 | Robl James M | Transgenic ungulates capable of human antibody production |
US7074983B2 (en) | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
US20060117395A1 (en) * | 1999-11-19 | 2006-06-01 | Hematech, Llc | Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates |
US20050183145A1 (en) * | 1999-11-19 | 2005-08-18 | Goldsby Richard A. | Production of ungulates, preferably bovines that produce human immunoglobulins |
US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
US20040072288A1 (en) * | 2000-12-22 | 2004-04-15 | Philippe Collas | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
US20060212952A1 (en) * | 2000-12-22 | 2006-09-21 | Philippe Collas | Methods for cloning mammals using reprogrammed donor chromatin or donor cells |
WO2002051997A1 (en) * | 2000-12-22 | 2002-07-04 | Aurox Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells |
US7253334B2 (en) * | 2000-12-22 | 2007-08-07 | Aurox, Llc | Methods for cloning non-human mammals using reprogrammed donor chromatin or donor cells |
US7736895B2 (en) | 2000-12-22 | 2010-06-15 | Kyowa Hakko Kirin Co., Ltd. | Methods for altering cell fate |
US20060110830A1 (en) * | 2001-08-27 | 2006-05-25 | Advanced Cell Technology, Inc. | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US20080076176A1 (en) * | 2001-08-27 | 2008-03-27 | Advanced Cell Technology, Inc. | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US7807863B2 (en) | 2002-11-08 | 2010-10-05 | Kyowa Hakko Kirin Co., Ltd. | Transgenic bovine having reduced prion protein activity and uses thereof |
US20050097627A1 (en) * | 2002-11-08 | 2005-05-05 | Robl James M. | Transgenic ungulates having reduced prion protein activity and uses thereof |
US20090165154A1 (en) * | 2002-11-08 | 2009-06-25 | Robl James M | Transgenic ungulates having reduced prion protein activity and uses thereof |
WO2004094611A3 (en) * | 2003-04-21 | 2007-01-25 | Univ Massachusetts | Reprogramming nuclear function with somatic cell cytoplasm |
WO2004094611A2 (en) * | 2003-04-21 | 2004-11-04 | University Of Massachusetts | Reprogramming nuclear function with somatic cell cytoplasm |
US8222480B2 (en) | 2003-06-10 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Hypertonic conditions for cell and oocyte enucleation |
WO2004111195A2 (en) * | 2003-06-10 | 2004-12-23 | Trustees Of The University Of Pennsylvania | Methods and use of zona-free therapeutic cloning |
US7683236B2 (en) | 2003-06-10 | 2010-03-23 | Trustees Of The University Of Pennsylvania | Enhanced production of cloned mammals by zona pellucida-free homologous mammalian embryo aggregation |
US20050005318A1 (en) * | 2003-06-10 | 2005-01-06 | Michele Boiani | Compositions and methods for the efficient and reproducible generation of clone animals of all developmental stages and methods of use thereof |
US20100212032A1 (en) * | 2003-06-10 | 2010-08-19 | Michele Boiani | Compositions and Methods for the Efficient and Reproducible Generation of Clone Animals of All Developmental Stages and Methods of Use Thereof |
WO2004111195A3 (en) * | 2003-06-10 | 2005-06-09 | Univ Pennsylvania | Methods and use of zona-free therapeutic cloning |
US7928285B2 (en) | 2004-04-22 | 2011-04-19 | Kyowa Hakko Kirin Co., Ltd. | Method of producing xenogenous antibodies using a bovine |
US20060041945A1 (en) * | 2004-04-22 | 2006-02-23 | Hematech, Llc | Transgenic animals and uses thereof |
US10501723B2 (en) | 2005-08-03 | 2019-12-10 | Astellas Institute For Regenerative Medicine | Methods of reprogramming animal somatic cells |
WO2007047766A3 (en) * | 2005-10-14 | 2008-12-24 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
US9097707B2 (en) | 2005-11-18 | 2015-08-04 | The Regents Of The University Of California | Photoreactive regulator of protein function and methods of use thereof |
US9629911B2 (en) | 2005-11-18 | 2017-04-25 | The Regents Of The University Of California | Photoreactive regulator of protein function and methods of use thereof |
US20070128662A1 (en) * | 2005-11-18 | 2007-06-07 | Isacoff Ehud Y | Photoreactive regulator of protein function and methods of use thereof |
US8309350B2 (en) | 2005-11-18 | 2012-11-13 | The Regents Of The University Of California | Photoreactive regulator of protein function and methods of use thereof |
US8114843B2 (en) * | 2005-11-18 | 2012-02-14 | The Regents Of The University Of California | Photoreactive regulator of protein function and methods of use thereof |
US20100240132A1 (en) * | 2007-02-23 | 2010-09-23 | Robert Lanza | Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells |
US8796021B2 (en) | 2007-02-23 | 2014-08-05 | Advanced Cell Technology, Inc. | Blastomere culture to produce mammalian embryonic stem cells |
US10584313B2 (en) | 2007-02-23 | 2020-03-10 | Astellas Institute For Regenerative Medicine | Method of producing a differentiated mammalian cell comprising culturing a single mammalian blastomere |
US9937233B2 (en) | 2010-08-06 | 2018-04-10 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9701965B2 (en) | 2010-10-01 | 2017-07-11 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9732128B2 (en) | 2010-10-22 | 2017-08-15 | Biotime, Inc. | Methods of modifying transcriptional regulatory networks in stem cells |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US8754062B2 (en) | 2011-12-16 | 2014-06-17 | Moderna Therapeutics, Inc. | DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides |
US8680069B2 (en) | 2011-12-16 | 2014-03-25 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of G-CSF |
US8664194B2 (en) | 2011-12-16 | 2014-03-04 | Moderna Therapeutics, Inc. | Method for producing a protein of interest in a primate |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9782462B2 (en) | 2012-04-02 | 2017-10-10 | Modernatx, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US9089604B2 (en) | 2012-04-02 | 2015-07-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US9061059B2 (en) | 2012-04-02 | 2015-06-23 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating protein deficiency |
US9050297B2 (en) | 2012-04-02 | 2015-06-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014197421A1 (en) | 2013-06-05 | 2014-12-11 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
US10961531B2 (en) | 2013-06-05 | 2021-03-30 | Agex Therapeutics, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US11274281B2 (en) | 2014-07-03 | 2022-03-15 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
US11422125B2 (en) | 2015-03-23 | 2022-08-23 | Astellas Institute For Regenerative Medicine | Assays for potency of human retinal pigment epithelium (RPE) cells and photoreceptor progenitors |
US11680941B2 (en) | 2015-03-23 | 2023-06-20 | Astellas Institute For Regenerative Medicine | Assays for potency of human retinal pigment epithelium (RPE) cells and photoreceptor progenitors |
Also Published As
Publication number | Publication date |
---|---|
NZ516236A (en) | 2004-12-24 |
JP2003503071A (ja) | 2003-01-28 |
MXPA01013450A (es) | 2003-09-04 |
EP1196426A1 (en) | 2002-04-17 |
IL147179A (en) | 2015-01-29 |
CN1362965A (zh) | 2002-08-07 |
AU782286B2 (en) | 2005-07-14 |
AU5902800A (en) | 2001-01-31 |
WO2001000650A1 (en) | 2001-01-04 |
IL147179A0 (en) | 2002-08-14 |
BR0012099A (pt) | 2003-07-29 |
US20170226475A1 (en) | 2017-08-10 |
CA2377515C (en) | 2013-09-03 |
US9580683B2 (en) | 2017-02-28 |
US20130104253A1 (en) | 2013-04-25 |
US20150132853A1 (en) | 2015-05-14 |
EP1196426A4 (en) | 2003-09-03 |
CA2377515A1 (en) | 2001-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9580683B2 (en) | ES cell cytoplasm or ooplasm transfer to rejuventate recipient cells | |
US20040199935A1 (en) | Cytoplasmic transfer to de-differentiate recipient cells | |
AU716956B2 (en) | Quiescent cell populations for nuclear transfer | |
NZ335407A (en) | Reconstituted animal embryos prepared by using unactivated oocytes as cytoplast recipients for nuclear transfer | |
US20090170203A1 (en) | Methods for female mammalian spermatogenesis and male mammalian oogenesis using synthetic nanobiology | |
AU2003271356B9 (en) | Quiescent cell population for nuclear transfer | |
Lagutina et al. | Age-Related Effect of Cells as Donors of Nuclei: On the Efficiency of the Development of Cloned Rabbit Embryos | |
AU2005202805B2 (en) | Unactivated oocytes as cytoplast recipients for nuclear transfer | |
AU2005246962A1 (en) | Quiescent cell population for nuclear transfer | |
JP2005523031A (ja) | 冷却死骸からのクローン化された仔の生産 | |
MXPA98001646A (es) | Poblaciones de celula inactiva para transferencia celular | |
AU2005202808A1 (en) | Unactivated oocytes as cytoplast recipients for nuclear transfer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |